A recent study validating urine diagnosis for cancer cell receptors in prostate cancer is eclipsing traditional methodology and warrants further steps toward FDA approval says…
Read More
The cancer (tumor) profiling market is expected to grow at a CAGR of 19.1% over the next four years. This growth directly reflects the public’s…
Cancer diagnostics technology continues to evolve, with emerging science based in precision medicine beginning to dominate the industry. Even though global markets are primarily focused…
As cancer rates continue to rise, patients increasingly bear the brunt of both the financial and emotional costs related to their diagnosis. In an effort…
While genetic testing has been used for years to diagnose cancer, it is now finding new application in the identification of cancerous mutations that will…
False positive cancer screening tests often lead to unnecessary and invasive biopsies that can emotionally, physically and financially devastate patients. To help move the focus…
The out-of-pocket price of many life-saving cancer medications continues to grow, while insurance companies continue to raise deductibles and copays. Patients, who are paying more…
The accuracy of the PSA diagnostic test for prostate cancer has come under increasing scrutiny. NuView Life Sciences is developing technology that will make identifying…
The healthcare industry is shifting towards a precision-based treatment model. NuView Life Sciences is at the forefront of the effort to develop new, targeted cancer…
Inaccurate and unnecessary cancer screening tests cost the U.S. healthcare system billions of dollars each year. New screening tools in development by NuView Life Science…
